Riociguat
(Difference between revisions)
Ossip Groth (Talk | contribs) m (→Some trials) |
Ossip Groth (Talk | contribs) m (bmc pharm tox 16 sp 1) |
||
Line 61: | Line 61: | ||
{{tp|p=21789188|t=2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=21789188&pmc=3138745&ti=Soluble%20guanylate%20cyclase%20stimulation%20prevents%20fibrotic%20tissue%20remodeling%20and%20improves%20survival%20in%20salt-sensitive%20Dahl%20rats%20|usr=}} | {{tp|p=21789188|t=2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=21789188&pmc=3138745&ti=Soluble%20guanylate%20cyclase%20stimulation%20prevents%20fibrotic%20tissue%20remodeling%20and%20improves%20survival%20in%20salt-sensitive%20Dahl%20rats%20|usr=}} | ||
{{utp|p=20613628|t=2010. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models |pdf=http://journals.lww.com/jhypertension/Abstract/2010/08000/Nitric_oxide_independent_stimulation_of_soluble.11.aspx|usr=}} | {{utp|p=20613628|t=2010. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models |pdf=http://journals.lww.com/jhypertension/Abstract/2010/08000/Nitric_oxide_independent_stimulation_of_soluble.11.aspx|usr=}} | ||
+ | |||
+ | ==Article Collections== | ||
+ | {{slink|l=http://www.moremed.org/MedlineBsuchtPMC.php?Q=%28BMC+Pharmacol+Toxicol[JOUR]+AND+16[VI]+AND+Suppl%201[IP]%29&F=AND%201500[PDAT]:2025[PDAT]&Z0=0&ZL=150&Y=&MTB=1&px1=proxy.nationallizenzen.de&px2=&px3=&px4= |Congress Abstracts on Guanylate Cyclase Inhibition 2015 |c= }} | ||
==Links== | ==Links== |
Revision as of 19:52, 2 February 2016
search term via moremed.org ' |
Riociguat |
Contents |
Core OA papers on Riociguat
Journal article, free access |
GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2015. Riociguat: Something new in pulmonary hypertension therapeutics? Extract PDF direct |
Journal article, free access |
GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2013. Riociguat for the treatment of pulmonary arterial hypertension Extract PDF direct |
Journal article, free access |
GET 2013. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2010. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Extract PDF direct |
Journal Paper, restricted access |
GET 2014. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension Extract PDF direct |
General outline of Pulmonary Hypertension
Journal article, free access |
GET 2013. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2015. Medical treatment update on pulmonary arterial hypertension Extract PDF direct |
Journal article, free access |
GET 2015. The molecular targets of approved treatments for pulmonary arterial hypertension Extract PDF direct |
Journal article, free access |
GET 2015. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2014. Drug Therapy for Chronic Thromboembolic Pulmonary Hypertension: A Review of the Comparative Clinical Effectiveness Extract PDF direct |
Journal article, free access |
GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension Extract PDF direct |
Journal article, free access |
GET 2013. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Extract PDF direct |
Journal article, free access |
GET 2014. Respiratory review of 2014: pulmonary thromboembolism Extract PDF direct |
Journal article, free access |
GET 2014. Novel and emerging therapies for pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2013. Chronic thromboembolic pulmonary hypertension: role of medical therapy Extract PDF direct |
Journal Paper, restricted access |
GET 2015. Pulmonary arterial hypertension: a review in pharmacotherapy Extract PDF direct |
Mechanism of action
Journal article, free access |
GET 2010. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Extract PDF direct |
Journal article, free access |
GET 2009. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Extract PDF direct |
Journal article, free access |
GET 2008. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Extract PDF direct |
Journal Paper, restricted access |
GET 2013. The chemistry and biology of soluble guanylate cyclase stimulators and activators Extract PDF direct |
Journal Paper, restricted access |
GET 2009. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension Extract PDF direct |
Journal Paper, restricted access |
GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct |
Journal Paper, restricted access |
GET 2009. NO-independent, haem-dependent soluble guanylate cyclase stimulators Extract [{| class="wikitable"; style="border: 1pt" |
Journal Paper, restricted access |
GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct |
|}
Some trials
Journal Paper, restricted access |
GET 2015. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) Extract PDF direct |
Journal Paper, restricted access |
GET 2015. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Extract PDF direct |
Journal article, free access |
GET 2014. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study Extract PDF direct |
Journal article, free access |
GET 2014. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema Extract PDF direct |
Journal article, free access |
GET 2015. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease Extract PDF direct |
Journal article, free access |
GET 2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
Journal article, free access |
GET 2013. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT Extract PDF direct |
Journal article, free access |
GET 2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study Extract PDF direct |
Journal article, free access |
GET 2015. Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food Extract [ PDF direct] |
Journal Paper, restricted access |
GET 2013. The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis Extract PDF direct |
Journal Paper, restricted access |
GET 2015. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies Extract PDF direct |
Journal article, free access |
GET 2015. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence Extract PDF direct |
Journal article, free access |
GET 2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Extract PDF direct |
Journal Paper, restricted access |
GET 2010. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models Extract PDF direct |
Article Collections
Weblink noncommercial ' |
[JOUR+AND+16[VI]+AND+Suppl%201[IP]%29&F=AND%201500[PDAT]:2025[PDAT]&Z0=0&ZL=150&Y=&MTB=1&px1=proxy.nationallizenzen.de&px2=&px3=&px4= {{{t}}}] |
Links
Weblink noncommercial ' |
Heise-Technol-Rev. Bericht zur Ehrung der Entwickler |
Wikipedia |
en-wiki |
de-wiki |
Books